Weather

67°F1:51 AM

Health

1 read

New Medicare Program Offers Weight Loss Drugs for Seniors at Reduced Costs

KVIA•Wednesday, July 1, 2026 at 1:33 PM•CNN Newsource

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

A new federal initiative called Medicare GLP-1 Bridge will provide eligible seniors access to weight loss medications at a significantly reduced price of $50 per month. This program, effective from Wednesday and lasting until December 2027, aims to address obesity-related health issues among older adults. To qualify, individuals must be over 18, enrolled in Medicare's Part D, and meet specific health criteria, such as having a BMI of 35 or higher. Experts emphasize that while cost reduction is beneficial, potential users should carefully consider the implications of using these medications. With obesity rates among seniors nearly doubling since the 1990s, this program could improve health outcomes for millions.

Key Details: • Medicare GLP-1 Bridge program starts Wednesday, offering weight loss drugs for $50/month. • Eligibility requires being over 18, enrolled in Medicare Part D, and having a qualifying BMI. • Program lasts until December 2027 and aims to reduce obesity-related health issues. • Experts caution that affordability should not be the only factor in deciding to use these medications.

health weight-loss obesity medicare seniors

People & Organizations

Centers for Medicare and Medicaid ServicesMedicareKFFDr. John BatsisBarbara Senich

Related Articles

Polio Survivor's Life in Iron Lung Ends at Age 78

The last American polio survivor who relied on an iron lung for over 70 years has passed away at the age of 78. This individual's long battle with the disease highlights the historical impact of polio in the United States and serves as a reminder of the importance of vaccinations in preventing such illnesses. The loss of this survivor marks a significant moment in the collective memory of polio's effects on American society. As the community reflects on her life, it underscores the ongoing need for public health awareness and vaccination efforts.

FDA Approves New Gene Therapy for Sickle Cell Disease in Children

The U.S. Food and Drug Administration has granted approval for a groundbreaking gene therapy aimed at treating children aged 2 and older suffering from sickle cell disease. This innovative treatment is significant as it offers a new option for managing a condition that affects thousands of children across the country. The approval marks a crucial advancement in medical care for those impacted by this hereditary blood disorder, potentially improving their quality of life and health outcomes. Families with children diagnosed with sickle cell disease should consult their healthcare providers about this new treatment option.

FDA Approves New Gene Therapy for Sickle Cell Disease in Children

The U.S. Food and Drug Administration has granted approval for a groundbreaking gene therapy aimed at treating children aged 2 and older suffering from sickle cell disease. This new treatment represents a significant advancement in managing this chronic condition, which affects the shape and function of red blood cells, leading to severe pain and health complications. The approval is expected to provide new hope for affected families and improve the quality of life for children dealing with this debilitating illness. Parents and healthcare providers should stay informed about the availability and administration of this therapy.

E. Coli Concerns Lead to Blueberry Recall in El Paso

A recall has been issued for frozen blueberries due to potential E. Coli contamination. Consumers are urged to either discard the affected blueberries or return them to the store where they were purchased for a full refund. This recall is crucial as E. Coli can pose serious health risks, especially to vulnerable populations. Residents should check their freezers for any frozen blueberries and take appropriate action to ensure their safety.